Intraperitoneal Interferon-α in Residual Ovarian Carcinoma: A Phase II Gynecologic Oncology Group Study
Authors:
- 1 October 1999
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 75 (1) , 10-14
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian CancerNew England Journal of Medicine, 1996
- Intraperitoneal immunotherapy for ovarian cancer with alpha interferonEuropean Journal of Cancer, 1992
- Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: Lessons learned from a gynecologic oncology group phase II trial of ip cisplatin and recombinant α-interferonGynecologic Oncology, 1992
- Intraperitoneal adoptive immunotherapy for peritoneal cancer.Journal of Clinical Oncology, 1990
- Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study.Journal of Clinical Oncology, 1990
- Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancerEuropean Journal of Cancer, 1990
- A phase I–II trial of intraperitoneal cisplatin and α-lnterferon in patients with persistent epithelial ovarian cancerGynecologic Oncology, 1990
- Intraperitoneal Cisplatin with Systemic Thiosulfate ProtectionAnnals of Internal Medicine, 1982
- Human leukocyte interferon therapy for advanced ovarian carcinomaAmerican Journal of Clinical Oncology, 1982
- SENSITIVITY OF HUMAN OVARIAN CARCINOMA CELLS TO INTERFERON AND OTHER ANTITUMOR AGENTS AS ASSESSED BY AN IN VITRO SEMI‐SOLID AGAR TECHNIQUE*Annals of the New York Academy of Sciences, 1980